Five hundred and twenty-seven cases of prostate cancer retrieved from TCGA GDC revealed significantly different prevalence of mutations across the majority of mutations identified ≥ 5% including TP53 (n = 13, 72.2% vs n = 70, 13.3%, P = 0.00001), AR (n = 6, 33.3% vs n = 4, 0.8%, P = 0.00001) and PTEN (n = 5, 27.8% vs n = 19, 3.6%, P = 0.00002). This evidence concerns the gene TP53 and prostate cancer.